But starting in 2004, when antiangiogenic therapies first became available, you can see that there has been a 70 to 100 percent improvement in survival for people with kidney cancer, multiple myeloma, colorectal cancer, and gastrointestinal stromal tumors.
但从2004年开始， 当开始应用反血管增生疗法之后， 你可以看到 病人的存活率 有70％到100％的提高。 这些数据是针对有肾癌，多发性骨髓瘤， 大肠癌，胃肠道间质瘤的病人的。